UK markets closed

Mylan N.V. (MYL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.22-0.24 (-1.66%)
As of 1:25PM EDT. Market open.

Mylan N.V.

Building 4
Trident Place Mosquito Way
Hatfield AL10 9UL
United Kingdom
44 1707 853 000

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees35,000

Key executives

NameTitlePayExercisedYear born
Mr. Robert J. CouryExec. Chairman1.83MN/A1961
Ms. Heather BreschCEO & Exec. Director5.64MN/A1969
Mr. Rajiv MalikPres & Exec. Director4.47MN/A1961
Mr. Anthony MauroChief Commercial Officer2.55MN/A1973
Mr. Paul B. CampbellChief Accounting Officer, Sr. VP & Corp. ControllerN/AN/AN/A
Ms. Melissa TrombettaHead of Global Investor RelationsN/AN/AN/A
Mr. Dennis ZelenyChief Human Relations OfficerN/AN/A1955
Ms. Deborah AutorSr. VP, Head of Strategic Global Quality & Regulatory PolicyN/AN/AN/A
Mr. Joseph F. HaggertyCorp. Sec.N/AN/AN/A
Mr. Roger D. Graham Jr.Pres of Mylan SpecialtyN/AN/A1964
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Corporate governance

Mylan N.V.’s ISS governance QualityScore as of 6 October 2020 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.